

ATLAS GLOBAL BRANDS INC.



Amended and Restated Management's Discussion & Analysis

For the three-month period ended June 30, 2023

May 8, 2024

This amended and restated MD&A replaces and supersedes the version previously filed on SEDAR.

Contents

INTRODUCTION	3
CORPORATE OVERVIEW.....	5
OVERALL PERFORMANCE	8
STRATEGY AND OUTLOOK	12
DISCUSSION OF OPERATIONS.....	12
SUMMARY OF QUARTERLY RESULTS.....	17
LIQUIDITY AND CAPITAL RESOURCES.....	18
PROPOSED TRANSACTIONS	19
OFF-BALANCE SHEET ARRANGEMENTS	19
RELATED PARTY TRANSACTIONS	19
CHANGES IN ACCOUNTING POLICIES INCLUDING INITIAL ADOPTION.....	20
FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS.....	20
OUTSTANDING SHARE DATA.....	23
RISKS AND UNCERTAINTIES	23
KEY DEVELOPMENTS SUBSEQUENT TO THE THREE MONTHS ENDED JUNE 30, 2023	25
ADDITIONAL INFORMATION	26
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION.....	26

INTRODUCTION

General

This amended and restated management's discussion and analysis of financial condition and results of operations ("**MD&A**") of Atlas Global Brands Inc. ("**Atlas**" or "**Company**") for the three months ended June 30, 2023 should be read in conjunction with the amended and restated condensed consolidated interim financial statements of the Company for the three and six months ended June 30, 2023 (the "**Interim Financial Statements**"), prepared in accordance with International Accounting Standard ("**IAS**") 34, *Interim Financial Reporting* of International Financial Reporting Standards ("**IFRS**"), as issued by the International Accounting Standards Board, and the audited annual consolidated financial statements of the Company for the financial year ended March 31, 2023 (the "**Annual Financial Statements**"). This MD&A complements and supplements but does not form part of the Company's condensed consolidated interim financial statements. All dollar amounts referred to in this MD&A are expressed in Canadian dollars except where indicated otherwise.

This MD&A replaces the management's discussion and analysis for the three months ended June 30, 2023 filed on April 9, 2023 ("**Original MD&A**") for the purpose of restating the information contained in the Original MD&A to align with changes made to the Company's interim consolidated financial statements for the three and six months ended June 30, 2023 filed on April 9, 2023 (the "**Original Financial Statements**"). **Specifically, the Original Financial Statements were restated to adjust for an overstatement** of inventory balance of \$1,635,493 as at June 30, 2023 and a corresponding understatement of cost of sales, see Note 28 in the financial statements for further information.

This MD&A has been prepared as of May 8, 2024 pursuant to the disclosure requirements under National Instrument 51-102 – Continuous Disclosure Obligations ("**NI 51-102**") of the Canadian Securities Administrators.

This MD&A contains forward-looking information and statements within the meaning of applicable securities laws. Statements regarding the adequacy of cash resources to carry out the Company's strategy and maintain operations are forward-looking statements. All forward-looking statements and information, including those not specifically identified herein, are made subject to the cautionary language below under the heading "Cautionary Statement Regarding Forward-Looking Information".

The Business Combination

On December 30, 2022, the Company (then Silver Phoenix Resources Inc. ("**Silver Phoenix**")) completed a business combination with Atlas Biotechnologies Inc. ("**Atlas Biotech**"), AgMedica Bioscience Inc. ("**AgMedica**") and Cambrosia Ltd. ("**Cambrosia**") and the concurrent acquisition by Cambrosia of a 51% interest in each of Tlalim Pappo Ltd., Pharmacy Baron Ltd., and R.J. Regavim Ventures Ltd. (together the "**Israel Pharmacies**"), each an independent and privately held pharmacy in Israel (all together, the "**Transaction**").

The Company completed the Transaction pursuant to an amalgamation and share exchange agreement dated July 14, 2022, as amended, among Silver Phoenix, Atlas Biotech, AgMedica, Cambrosia, 2432998 Alberta Ltd. ("**Subco 1**"), 14060407 Canada Inc. ("**Subco 2**") and the ordinary shareholders of Cambrosia (the "**Amalgamation and Share Exchange Agreement**").

The Transaction constituted a "fundamental change" of the Company pursuant to the policies of the Canadian Securities Exchange (the "**CSE**").

The Transaction was structured as a three-cornered amalgamation and share exchange, pursuant to which (i) Subco 1, a wholly-owned subsidiary of the Company and Atlas Biotech, amalgamated (the "**Atlas Amalgamation**") to form a newly amalgamated company ("**Atlas Amalco**"); (ii) Subco 2, a wholly-owned subsidiary of the Company and AgMedica, amalgamated (the "**AgMedica Amalgamation**") to form a newly amalgamated company ("**AgMedica Amalco**"); (iii) the Company acquired all of the issued and outstanding securities of Cambrosia pursuant to a share exchange with the holders thereof (the "**Cambrosia Share Exchange**"); and (iv) Cambrosia acquired a 51% interest in each of the Israel Pharmacies (collectively, the "**Cambrosia Acquisitions**").

Concurrently, with the completion of the Transaction, Cambrosia completed a financing pursuant to which it issued 100,000,000 ordinary shares of Cambrosia to S.H.R. Group Management (KSN) Ltd. ("**S.H.R. Group**") for gross proceeds of ILS 9,000,000 (approximately CAD\$3,487,441).

Pursuant to the terms of the Amalgamation and Share Exchange Agreement, immediately prior to closing, Silver Phoenix consolidated its shares on a 244,139 to 1 basis resulting in 3,445,380 shares outstanding post-consolidation, and all issued and outstanding Silver Phoenix warrants were cancelled.

Pursuant to the Atlas Amalgamation, former holders of common shares of Atlas Biotech received an aggregate of 38,550,838 post-consolidation shares of the Company on a pro-rata basis and Atlas Amalco became a wholly owned subsidiary of the Company.

Pursuant to the AgMedica Amalgamation, former holders of common shares of AgMedica received an aggregate of 38,550,870 post-consolidation shares of the Company, on a pro rata basis and AgMedica Amalco became a wholly owned subsidiary of the Company.

Pursuant to the Cambrosia Share Exchange, the former holders of ordinary shares of Cambrosia and vendors of the Israel Pharmacies received an aggregate of 62,282,313 post-consolidation shares of the Company together with options to acquire an additional 2,621,027 post-consolidation common shares of the Company and Cambrosia became a wholly owned subsidiary of the Company.

The Company completed the Transaction as of December 30, 2022, and on January 13, 2023 its common shares (the "**Shares**") began trading on the CSE under the symbol ATL.

Presentation of the Financial Statements

Cambrosia as Accounting Parent

The result of the Transaction is that the shareholders of Cambrosia effectively gained control of the Company, thereby constituting a reverse acquisition per IFRS 3.B19 whereby the Company (the legal parent) has been treated as the accounting subsidiary and Cambrosia (the legal subsidiary) has been treated as the accounting parent.

Silver Phoenix did not meet the definition of a business under IFRS 3 – *Business Combinations*, and therefore the Transaction was treated as an asset acquisition and not as a business combination and was accounted for as a capital transaction under IFRS 2 – *Share-Based Payments* for the acquisition of the net assets of Silver Phoenix and its listing status on the CSE. The balance of the Transaction constituting the acquisitions of AgMedica, Atlas Biotech and the Israel Pharmacies have all been accounted for in the Annual Financial Statements as a single business combination under IFRS 3.

Comparative Period in Interim Financial Statements

Section 4.3(2) (b) of NI 51-102 requires that interim financial reports include a statement of comprehensive income, a statement of changes in equity and a statement of cash flows, all for the year-to-date interim period, and comparative financial information for the corresponding interim period in the immediately preceding financial year, if any. Pursuant to section 4.10(3) of NI 51-102, a reporting issuer is not required to provide comparative interim financial information for the reverse takeover acquirer for periods that ended before the date of the reverse takeover if: (a) to a reasonable person it is impracticable to present prior period information on a basis that is consistent with subsection 4.3(2); (b) the prior information that is available is presented; and (c) the notes to the interim financial report disclose the fact that the prior period information has not been prepared on a basis consistent with the most recent interim financial information.

As stated above, Cambrosia has been treated as the reverse takeover acquirer for the purposes of the Interim Financial Statements. As a private company existing under the laws of Israel, Cambrosia did not prepare interim financial statements (for internal or external purposes) prior to completion of the Transaction in December 2022. As such, the Company determined that the absence of a cut-off date of March 31, 2022 (required to present financial information for the three month period ended June 30, 2022), made it impracticable for a reasonable person to present financial information that is consistent with subsection 4.3(2)(b). In accordance with subsection 4.10(3)(b) of NI 51-102 then, the Interim Financial Statements, include a statement of comprehensive income, a statement of changes in equity and a statement of cash flows, all for the three month period ended June 30, 2023, and comparative financial information for the six month period ended June 30, 2022.

In addition, Cambrosia, the accounting parent, was incorporated on March 17, 2021. Prior to completion of the Transaction Cambrosia's business was focused on completing the Transaction and its results of operations for the six month period ended June 30, 2022, have limited comparative value as against the results of the operations of the Company during the three month period ending June 30, 2023, after giving effect to the Transaction. See "The Business Combination" above for further details regarding these mergers and acquisitions.

Use of Non-GAAP Measures

The Company reports its financial results in accordance with IFRS. However, throughout this MD&A, we discuss non-GAAP financial performance measures that are not recognized or defined under IFRS, including reference to:

- Net revenue;
- Net revenue from cannabis operations;
- Earnings before interest, depreciation, taxes and amortization ("**EBIDTA**");
- Adjusted EBITDA;
- Working capital; and
- Cannabis inventory and bio assets.

All these non-GAAP financial performance measures should be considered in addition to, and not in lieu of, the financial measures calculated and presented in accordance with IFRS. These measures are presented to help investors' overall understanding of our financial performance and should not be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These non-GAAP financial measures reflect an additional way of viewing aspects of operations that, when viewed with IFRS results, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review the Company's financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

Please see "Reconciliation of Non-GAAP Financial Measures to IFRS Measures" below for a reconciliation of such non-GAAP Measures to the most directly comparable IFRS financial measures.

CORPORATE OVERVIEW

General

Silver Phoenix was incorporated on February 14, 2003, under the *Business Corporations Act* (British Columbia) which is the date of inception of the Company from a legal operational perspective. Cambrosia was incorporated on March 17, 2021, which is the inception date of the financial information presented in the Interim Financial Statements.

The Company is listed on the CSE under the trading symbol ATL. The address of the Company's corporate office and principal place of business is 566 Riverview Drive, Unit 104, Chatham, O.N., N7M 0N2 and its registered and records office is located at Suite 3000, 1055 West Dunsmuir Street, Vancouver B.C. V7X 1K8.

The Company's principal business activity is the production, distribution and sale of cannabis internationally and in Canada. Our medical cannabis is currently sold and distributed in Canada, Australia, Germany, Israel, Denmark, Norway, Spain, and United Kingdom and we sell cannabis for the adult recreational market in Canada. As at June 30, 2023, the Company had the following subsidiaries:

<u>Name of Subsidiary</u>	<u>Jurisdiction of Incorporation</u>	<u>Ownership Interest</u>	
		June 30, 2023	March 31, 2023
Atlas Global Brands Inc.	Canada	100%	100%
Tlalim Papo Ltd.	Israel	51%	51%
Pharmacy Baron Ltd.	Israel	51%	51%
R.J. Regavim Ventures Ltd.	Israel	51%	51%
AgMedica Bioscience Inc.	Canada	100%	100%
5047346 Ontario Inc.	Ontario	100%	100%
Tavivat Naturals Inc.	Canada	100%	100%
8050678 Canada Inc.	Canada	100%	100%
Unique Beverages (USA) Inc.	USA	100%	100%
Wellworth Health Corp.	Canada	100%	100%
GreenSeal Cannabis Company, Ltd.	Canada	100%	-%
GreenSeal Nursery, Ltd.	Canada	100%	-%
Atlas Biotechnologies Inc.	Alberta	100%	100%
Atlas Growers Ltd.	Alberta	100%	100%
Atlas Growers Denmark A/S	Denmark	100%	100%

Facilities

As at June 30, 2023 the Company operated two licensed facilities in Canada: (1) an EU-GMP, GACP and CUMCS certified facility in Chatham, Ontario; and (2) a GACP certified facility in Stratford, Ontario, as well as three (3) pharmacies in Israel, all of which were acquired on December 30, 2022 as part of the Transaction further described above.

The Company utilizes its fully integrated and GACP, IMC-GAP and EU-GMP growing facility in Chatham, Ontario for cultivation, packaging, and processing and as its hub for exports to international markets. The Company utilizes the cultivation from its GACP and IMC-GAP certified facility in Stratford, Ontario to augment fulfillment of the international demand as well as to satisfy demand in the domestic Canadian market.

In Israel, the Company uses the Israeli Pharmacies to sell product directly to patients. By having a controlling interest in these pharmacies, Atlas is assured increased shelf space, premium product placement and availability.

Chatham, Ontario

The Company owns 215,000 sq. ft. industrial building at 566 Riverview Drive, in Chatham, Ontario, of which 110,000 sq. ft. is a dedicated indoor growing, processing and drying facility (the “**Chatham Facility**”). The Chatham Facility has current growing capacity of approximately 6,500 kg/year.

The Chatham Facility is a purpose-built cannabis facility at which AgMedica cultivates crop using a three or four vertical tiered system. This system allows precise control growing conditions for each plant group and maximizes production per square foot within each grow room. The AgMedica Facility offers the ability to cultivate year-round, resulting in slightly more than five flowering room turns per year.

The Chatham Facility has six active three-tiered grow rooms and five active larger scale grow rooms with four vertical tiers.

Additionally, the Chatham Facility has been licensed for six additional larger scale grow rooms with four vertical tiers, which have yet to be onboarded into active production. These additional grow rooms have been structurally completed but require additional infrastructure investments prior to onboarding them into active production (the “**Chatham Expansion**”). It is estimated that the Chatham Expansion could expand capacity by an additional 6,000+ kgs/annually.

The Chatham Facility is currently only approximately 50% occupied by AgMedica. AgMedica currently rents a portion of the remaining industrial space to third-party tenants to generate non-core cash flow.

Following the closure of the Gunn Facility (as defined below), the Chatham Facility became the hub for processing of cannabis flower, 1.0 and 2.0 products, and oils.

Stratford, Ontario

As a result of its acquisition of GreenSeal (described in detail below), the Company owns a 30,000 square foot facility in Stratford, Ontario which produces just over 3,500 kg of cannabis flower annually (the “**Stratford Facility**”). Within a two-hour drive of the Chatham Facility, the Stratford Facility offers operational efficiencies. The Stratford facility is also structured as a multi tier vertical grow facility, growing flower, and drying it indoors.




Israel


As previously stated, the Company has a 51% interest in the three Israel Pharmacies, located in Tel Aviv, Israel, two of which are licensed under the Medical Cannabis Unit of the Israeli Ministry of Health to dispense medical cannabis and an application has been submitted in respect of the third pharmacy.

Products

We currently have approximately 50 distinct products available for sale across Canada varying in availability province to province. The Company has direct supply agreements in place with the British Columbia Liquor Distribution Branch, the Alberta Gaming, Liquor and Cannabis Commission, the Ontario Cannabis Stores, the Yukon Liquor Corporation and sells directly to Manitoba Liquor & Lotteries, the Northwest Territories Liquor, Cannabis Commission, and the PEI Cannabis Management Corporation. We also have distribution agreements with distributors in Saskatchewan who distribute the Company's products to certain provincial distributors and retailers.

The Company's primary products are currently as follows:

Brand	Description	Market Segment (economy, value, core, premium or premium +)
	Nurtured and curated using old school techniques of hang drying, hand trimming and cured to perfection.	PREMIUM+
	Standard approach, consistent craft experience with a genetic forward focus.	PREMIUM
	Accessible and convenient, with fun and unique flavours and products.. Offering a rotation of products featuring single strain, premium quality flower. Cultivated indoors with precision: hang dried, hand trimmed, and cured for weeks to ensure full flavour and potency.	VALUE

	Craft cannabis, grown in small batches, harvested at peak ripeness, hang dried, and hand trimmed without the use of machines. Bonfire product is all grown indoors using exclusive genetics sourced from our in-house nursery.	CORE
---	--	------

OVERALL PERFORMANCE

General

During the three months ended June 30, 2023, the Company had net income of \$5,678,991 and as at June 30, 2023 had a cumulative deficit of \$10,828,990 and current liabilities exceeding current assets by \$20,314,417. Accordingly, there is a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

Concurrent with the closing of the Transaction, the Company appointed a new Chief Executive Officer and Chief Financial Officer, not previously associated with the Company nor any of the entities included in the Transaction. As such, during the three-month period ended March 30, 2023, efforts were dedicated towards implementing changes in the Company's existing operations to address urgent liquidity issues, harmonize the consolidated cost structure and ultimately, reduce costs, optimize operations, improve cash flow and shift focus to the higher margin international market.

In the three month period ended June 30, 2023, management continued these efforts and implemented the more material operational changes, including in particular the closure of the Gunn Facility and acquisition of GreenSeal, each as discussed in detail below.

Acquisitions in Israel

Harmony

On February 6, 2023, the Company announced the proposed acquisition of a 51% controlling interest in a private limited liability company ("**Harmony**") operating two medical cannabis pharmacies, one in Tel-Aviv and one in Jerusalem, and a 51% interest in an Israeli licensed cannabis "Trading House" intended to serve as the Company's hub for imports to and distribution within Israel, for consideration consisting of up to 2,800,702 Shares of the Company, at a deemed price of \$1.00 per Share.

During the three months ended June 30, 2023, the Company lent the Trading House approximately \$75,000 in addition to the approximate \$375,000 advanced in prior periods, bringing the total amount lent to the Trading House as at June 30, 2023 to approximately \$450,000 which is guaranteed by the Harmony vendors, to be repaid immediately in the event the transaction does not close.

Subsequent to June 30, 2023, the Company advanced a further \$75,000 and also entered into revenue transactions with the vendors.

Owing to disputes regarding, among other matters, payment for product, the acquisition agreement was terminated in accordance with its terms, on the basis that the transaction was not completed by the date prescribed for completion in the definitive agreement.

On December 20, 2023, Cambrosia filed a lawsuit against the principals of Harmony in the District Court of Tel Aviv, seeking various remedies including repayment of a loan in the amount of NIS 1,431,838 (approx. CAD \$525,000) as noted above.

As part of the claim, the Company asked the court for a lien on the bank accounts of Harmony and its four founders. On December 21, 2023 the court approved the Company's request and issued a lien on those accounts in an amount of NIS 2,137,226 (approx. CAD \$783,293), on each of the accounts of all six defendants. Following a request by the Company, on December 25, 2023, the court issued new liens on the accounts of all defendants, revising the amount of the liens to NIS 3,291,764 (approx. CAD \$1,206,431) in each account.

Hi Times

On May 17, 2023, the Company announced the proposed acquisition of a 51% controlling interest in a private limited liability company operating a medical cannabis pharmacy, doing business as "Hi Times", for consideration of approximately 1,132,000 Shares of the Company at the deemed issue price of \$1.00 per Share, and approximately CAD \$239,743, payable at closing (the "**Cash Consideration**"). Had the transaction closed, the Cash Consideration may have been increased by up to New Israeli Shekel ("**NIS**") 2,050,000 upon the pharmacy's revenue and profitability exceeding certain prescribed amounts for the financial years ending December 31, 2023, to 2025.

The transaction was subject to the receipt of applicable regulatory approvals in Israel, which were not received by the agreed deadline for consummating the transaction. As a result, the transaction lapsed. Numerous attempts to negotiate a new agreement have not succeeded.

Duda

On May 24, 2023, the Company announced the proposed acquisition of a 51% controlling interest in Umana Pharmacies Ltd (doing business as "Duda"), which owns three private limited liability companies for consideration of approximately \$3,411,444, comprised of a cash payment and the issuance of 1,925,300 Shares of the Company at the deemed issue price of \$1.00 per share. Duda operates pharmacies which are used to distribute medical cannabis in Israel.

The transaction was subject to the receipt of applicable regulatory approvals in Israel which were not received by the agreed deadline for consummating the transaction. As a result, the transaction was terminated pursuant to its terms.

GreenSeal Acquisition

On April 28, 2023, the Company acquired all of the issued and outstanding shares of GreenSeal Cannabis Company, Ltd. and GreenSeal Nursery Ltd. (together, "**GreenSeal**"), a privately owned Ontario-based licensed cannabis producer and nursery pursuant to a share purchase agreement dated February 24, 2023, as amended, among the Company, GreenSeal and the shareholders of GreenSeal (the "**Share Purchase Agreement**").

Pursuant to the Share Purchase Agreement, Atlas Global issued to the GreenSeal vendors an aggregate of 7,612,358 Shares at an issue price per share equal to CAD \$0.4374, representing the 20-day volume weighted average closing price (the "**VWAP**") of the Company's Shares on the CSE prior to closing. A further 2,387,642 Shares have been reserved for issuance to the GreenSeal vendors under the Share Purchase Agreement in connection with certain withholding obligations of the Company (the "**Withheld Shares**"). Up to an additional 1,500,000 shares may be issued at the 12-month anniversary of the closing date of the acquisition (the "**Closing Date**") based on the then VWAP of the Shares.

Approximately \$5.5M in bank debt and \$0.6M in long-term loans remain with GreenSeal post-closing, including a loan by an employee of GreenSeal that was guaranteed by the Company as a condition to closing the transaction. The Shares are subject to a contractual lock-up, pursuant to which 15% of the Shares are released every six months commencing on the six-month anniversary of the Closing Date, until the 36-month anniversary of the Closing Date. If, the volume weighted average closing price per share for the 20 trading days preceding the share releases on the 18, 24, and 30-month release dates is at least CAD \$2.00, an additional 5% of the Shares will be released on such release date.

The following table summarizes the preliminary fair value of the assets and liabilities acquired and consideration paid for GreenSeal:

Fair value of share consideration

Common shares issued ⁽ⁱ⁾	\$	2,521,118
Common shares to be issued ⁽ⁱⁱ⁾		790,757
Contingent consideration ⁽ⁱⁱⁱ⁾		308,562

Total consideration paid for transaction	\$	<u>3,620,437</u>
Net assets acquired		
Net working capital	\$	2,051,670
Biological assets		792,603
Property, plant and equipment		9,913,000
Right of use assets		570,230
Right of use liabilities		(570,230)
Intangible assets		25,000
Contingent liability ^(iv)		(1,058,172)
Debt		<u>(6,013,518)</u>
Total net assets acquired		<u>5,710,583</u>
Gain on bargain purchase	\$	<u>2,090,146</u>

- (i) Share consideration: The share consideration has been determined based on the fair value of the Company's shares on the closing date of the transaction.
- (ii) Shares to be issued: 2,387,642 common shares have been reserved for issuance to the GreenSeal vendors under the Share Purchase Agreement in connection with certain withholding obligations of the Company.
- (iii) Contingent consideration: Up to an additional 1,500,000 shares may be issued at the 12-month anniversary of the closing date of the acquisition based on the then share price of the Company's common shares.
- (iv) Contingent liability: As part of the GreenSeal acquisition, the Company recognized a liability related to past investment tax credits received by GreenSeal which may be repayable in the future. The timing of any repayment is uncertain.

Closure of the Gunn, Alberta Facility

On June 2, 2023, the Company announced that it would cease operations at its facility in Gunn, Alberta and liquidate the assets of Atlas Biotech and Atlas Growers Ltd., respectively (together, the "**Atlas Subsidiaries**"). Approximately 50 employees were impacted by this decision. All packaging activities were relocated to the Chatham Facility.

On June 5, 2023, the Atlas Subsidiaries received demand notices from its senior lender demanding payments of loan owing to them within 10 days of receiving the notices failing which legal action and/or realization proceeding may be commenced. The demand notices also included a notice of intention to enforce security pursuant to the Bankruptcy and Insolvency Act. Based on financial analysis and after careful consideration of available alternatives, as based on the cash positions of the Company and its subsidiaries, forecasted revenue and expenses, scheduled debt payments and demands for payment received from creditors and the operational capabilities of the Company's other business units in Ontario, it was determined to be in the best interests of the Company and its shareholders to have the assets of the Atlas Subsidiaries liquidated, through a court-supervised process, in an orderly fashion so as to maximize recoveries for all affected stakeholders.

At the Company's suggestion and with the Company's cooperation, on June 27, 2023, the Atlas Subsidiaries' senior lender, the Agriculture Financial Services Corporation (the "**AFSC**") filed a statement of claim against the Company with the Court of King's Bench of Alberta in connection with the enforcement of the indebtedness of Atlas Biotech to the AFSC as well as the existing \$1,400,000 limited parental guarantee of the Company and the personal guarantees of certain former principals of the Atlas Subsidiaries.

Effective July 4, 2023, on the application of the AFSC and with the consent of the Company, Ernst & Young Inc. was appointed as receiver and manager over certain current and future assets of the Atlas Subsidiaries, under the *Bankruptcy and Insolvency Act* (Canada) and the *Personal Property Security Act* (Alberta).

The following table summarizes the net impact of deconsolidation of the Atlas Subsidiaries as reported in the Interim Financial Statements:

Net Assets deconsolidated as at June 30, 2023		
Cash	\$	34,691
Trade and other receivables		604,623
Inventories		635,418
Deposits and prepaid expenses		431,146
Intercompany and other receivables		454,152
Property, plant & equipment		<u>4,761,514</u>

Right-of-use assets		215,908
Trade and other payables		(8,569,573)
Term Debt		(10,761,357)
Lease liabilities		(238,707)
Net assets of Atlas Subsidiaries	\$	(12,432,185)
Parental guarantee liabilities	\$	2,896,341
Gain on loss of control	\$	9,535,844

Operational Changes

Commencing with initial samples in May 2023 followed by first commercial exports in July 2023, operations at the Chatham Facility were expanded to include EU-GMP vape production.

Coincident with the liquidation of the Atlas Subsidiaries and consequential cessation of operations at the Gunn Facility, the Company shifted the focus of its activity at the Stratford Facility on growing, processing and packaging for the domestic Canadian market while continuing to breed unique genetics for both the domestic and international markets. This shift has enabled the Company to enhance yields and the proportion of Grade A flower at both its Chatham Facility and Stratford Facility.

Industry and Economic Factors Affecting Our Business

The following industry and economic factors have and are anticipated to continue to affect the Company's performance.

Canadian cannabis market trends

- **Price compression.** We have historically seen and continue to see price compression in the market, when compared to the prior fiscal year, which was driven by intense competition from the approximately 800 licensed producers in Canada. The price compression year over year has reduced the Company's revenue and has made growing market share a challenge.
- **Excise tax Rates.** Given the impacts of the above-referenced price compression, excise tax has grown to become a larger component of net revenue as it is predominantly computed as a fixed price on grams sold rather than as a percentage of the selling price. In late February 2024, the House of Commons Standing Committee on Finance issued a report outlining several recommendations regarding the adult-use cannabis industry. One such recommendation was a request to "make adjustments to the excise duty formula for cannabis so that it is limited to a 10% ad valorem rate and a requirement to apply an excise stamp on cannabis products. While the Company believes that in the long term there is a possibility of some level of reform, it will likely not occur in the next 12 months.**Excise Tax Arrears.** Separately, as of March 1, 2024 it was reported that approximately \$200M was owed to the Canada Revenue Agency (the "CRA") in excise tax in arrears. These arrears prompted the CRA to request that provincially owned cannabis wholesalers to garnish payments intended for licensed producers, such as the Company. The Company has an arrears balance with the CRA and the potential garnishment of payments, without third party financing and/or some negotiation of the timing of payment of the arrears will materially adversely affect the Company's future financial performance.
- **Inflation.** The Company's financial performance has been affected by global inflationary pressures, commensurate with other companies in the cannabis industry.

International cannabis market trends

The cannabis industry in Europe is in its early stages of development, and countries within Europe are at different stages of legalization of medical and adult-use cannabis. Some countries have expressed a clear political ambition to legalize adult-use cannabis, some are engaging in an experiment for adult-use, and some are debating regulations for cannabinoid-based medicine.

For example, on March 22, 2024, it was announced that cannabis possession and home cultivation will be decriminalized in Germany from April 1, 2024. The decriminalization legislation is what is known as the "first pillar" in a two-step plan to legalize cannabis in the country. The "second pillar" is expected after the decriminalization bill and would set up municipal five-year pilot programs for state-controlled cannabis to be sold in licensed shops.

Overall, then, in Europe, we believe that, despite continuing recessionary economic conditions and the Russian conflict with Ukraine, cannabis legalization (both medicinal and adult-use) will continue to gain traction albeit more slowly than originally expected.

STRATEGY AND OUTLOOK

Atlas believes that profitable growth, smart capital allocation and balance sheet health are critical success factors in the dynamic and rapidly developing global cannabis industry.

On the basis of the industry and economic trends discussed above, we believe that our international medical cannabis business provides the foundation for profitability and positive cash flow, and so we continue to increase distribution in core international markets and use the Canadian consumer business as a platform to build brands particularly through partnerships such as that with Snoop Dogg.

As such and given the Company's current cash flow concerns and continuing losses, the Company's primary strategy is to secure a short term loan of up US\$3 to \$5 million to address immediate liquidity needs, refinance its Chatham Facility to complete the Chatham Expansion and increase its market share in the higher margin international medical cannabis market while adding a high margin revenue stream in the form of co-packing cannabis and cannabis accessories for export.

This strategy is heavily dependent on securing third party financing, absent which the Company have consider a reduction in corporate capacity and/or sale or liquidation of non-core assets.

DISCUSSION OF OPERATIONS

Summary

As previously stated, Cambrosia, the accounting parent, was incorporated on March 17, 2021 and had limited operations until completion of the Transaction on December 30, 2022. While Atlas Biotech and AgMedica were operational prior to the Transaction date having substantial revenues in 2022, their respective pre-amalgamation results are not consolidated in the above financial data under IFRS accounting standards.

As a result, a discussion of the Company's results of operations during the three month period ended June 30, 2023 as compared to the corresponding period in the prior year is of very little value to the reader. A discussion of the Company's financial performance in comparison to that of the corresponding period of the preceding financial year will be of value commencing with the three month period ended June, 30, 2024, which will be comparable to the three months ended June 30, 2023.

Similarly, the operating results of the Company for the 15 month period ended March 31, 2023 (being the most recently completed financial year), only include three months of the operating results of the Company after giving effect to the Transaction.

The following is a summary of the Company's operating results for the three months ended June 30, 2023 and the most recent 15 month fiscal year ended March 31, 2023.

	3 Months ended June 30, 2023	15 Months ended March 31, 2023
Financial Results		
Revenue	\$ 7,329,712	6,212,241
Net revenue from cannabis operations ⁽¹⁾	4,464	5,109,776
Gross profit	4,446,755	813,754
Operating expenses	5,838,799	8,512,685
Net income (loss)	5,678,991	(289,046)
EBIDTA ⁽²⁾	8,186,688	(7,245,758)
Adjusted EBITDA ⁽²⁾	360,614	(3,824,806)

Statement of Financial position

Working capital (deficiency) / surplus ⁽³⁾	(20,314,417)	(25,432,813)
Cannabis inventory and bio assets ⁽⁴⁾	15,429,658	12,893,684
Shareholder (equity) deficit	(18,205,139)	(9,132,359)
Total assets	64,980,691	61,653,037

Notes:

These terms are defined in the "Cautionary Statement Regarding Certain Non-IFRS Performance Measures" section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure.

- (1) Refer to the "Net Revenue" section for a reconciliation to the IFRS equivalent.
- (2) Refer to the "EBITDA" section for a reconciliation to the IFRS equivalent.
- (3) "Working capital" is defined as current assets less current liabilities as reported on the Company's Consolidated Statements of Financial Position. Current Liabilities includes the current portion of convertible debentures.
- (4) Represents total biological assets and inventory, accessories, supplies, consumables, and plant propagation biological assets.

The Company has not paid any dividends for the periods represented above.

Revenue

The Company's revenue is comprised of the domestic and export sales of our three wholly owned Canadian subsidiaries, AgMedica, Atlas Biotech, and GreenSeal and the revenues of the Israel Pharmacies.

The Company generates revenue from the cultivation, distribution, wholesale and pharmaceutical dispensing of cannabis and cannabis related products within the domestic and international markets ("**Cannabis revenue**") as well as non-cannabis medicines and over the counter consumer packaged goods at its pharmacy locations in Israel ("**Non-cannabis revenue**").

The results of AgMedica and the Israel Pharmacies are included for the entire reporting period. Atlas Biotech's results are included from the beginning the period on April 1, 2023 through to its liquidation on June 26, 2023 with the resulting deconsolidation and abnormal losses reported in other income and expenses. GreenSeal is included in the consolidated results from day following the acquisition closing, April 29, 2023, through to the end of the reporting period.

During the period, Cannabis revenue was 5,272,691 and Non-cannabis revenue was \$2,057,022 for total revenue of \$7,329,713 compared to \$6,212,241 for the 15 month period ended March 31, 2023, (and again only the last three months of which period represented the results of each of the entities acquired in the Transaction). The increase from \$6,212,241 to \$7,239,713 during the three months ended June 30, 2023 is primarily attributable to the acquisition of GreenSeal during the period and the increase in sales following the launch of the Company's product collaboration with Snoop Dogg.

Net Cannabis Revenue

Net revenue represents revenues from the sale of cannabis products less excise taxes. Only the Company's Cannabis revenue is subject to excise tax. Cannabis revenue of \$5,272,691 and excise taxes of \$808,426 were recorded in the period, resulting in net Cannabis revenue of \$4,464,264 and total net revenue of \$6,521,286. See Note 18 in the Interim Financial Statements for further information on net revenues from cannabis products.

The following is a breakdown of net revenues based on the geographical region.

		For the 3 month period ended June 30, 2023	%	For the 3 month period ended March 31, 2023	%	Quarter to Quarter Growth
Canadian revenues	\$	2,978,360	46%	2,092,509		42%
International revenues:						
Oceania		1,910,000	29%	2,073,350		-8%
Asia		1,168,540	18%	1,194,290		-2%
Europe		464,386	7%	441,186		5%

Net revenue	\$	6,521,286	100%	5,801,335	12%
-------------	----	-----------	------	-----------	-----

Net revenue growth is driven by the Canadian launch of the D Lbs products arising from the partnership with Snoop Dogg. International revenues were consistent quarter to quarter with D Lbs launches planned in subsequent quarters leveraging the insights gathered by the domestic launch.

Gross Profit

Gross profit of \$4,446,755 is primarily driven by the recognition of unrealized gains of \$3,655,760 on changes in fair value of biological assets developed in the period.

Operating Expenses

Selling, general and administrative (“SG&A”) expenses of \$5,838,083 include, in material part, legal and professional fees of \$757,747 relating to the acquisition of GreenSeal, the closure of the Gunn Facility and the negotiation and termination of the purchase agreements to acquire assets in Israel, as described above. See Note 19 of the Interim Financial Statements for a detailed breakdown of SG&A for the period.

Net Income

The net income for the three-month period ended June 30, 2023 of \$5,678,991, includes the gain on bargain purchase resulting from the GreenSeal acquisition of \$2,090,146 and the gain on loss of control resulting from the liquidation of the assets of the Atlas Subsidiaries of \$9,535,844, partially offset by the loss from abnormal destruction of the Atlas Biotech inventories and biological assets of \$3,514,649.

Positive net income in the quarter is a result of the one-time gains described above. It is expected that these will be nonrecurring in nature. Please see below for discussion on Adjusted EBITDA as an indicator of underlying performance.

EBITDA

EBITDA is defined as earnings (loss) before interest, taxes, depreciation and amortization. Adjusted EBITDA is EBITDA less adjustments for non-recurring items.

EBITDA for the period was \$8,186,688 driven by the gain from the de-consolidation of the Atlas Subsidiaries. See Note 5 in the Interim Financial Statements. EBITDA for the period also includes \$2,090,146 bargain purchase gain resulting from the acquisition of GreenSeal. See Note 4 in the Interim Financial Statements.

Adjusted EBITDA

Adjusted EBITDA is EBITDA adjusted for abnormal and non-recurring items as outline below, adjusted EBITDA was \$360,614. The improvement in adjusted EBITDA reflects the activities of management on the implementation of its strategies including the harmonization and the consolidation of the Company's cost structure, optimization of operations, and shift of focus to the higher margin international market.

Although management believes the Adjusted EBITDA figure is indicative of underlying performance, it expects there to be fluctuations as we continue the implementation of our strategies and balance the cost and benefit realization over the coming quarters.

Working Capital

As at June 30, 2023, there was a working capital deficiency of (\$20,314,417) primarily due to the classification of the Company's term debts in the amount of \$21,291,775, as current. Working capital is further influenced by short-term liabilities, including government remittances of \$5,311,959 and other accounts payable of \$6,443,330 offset by inventory and biological assets of \$15,429,658 and trade and other receivables of \$3,775,787.

Cannabis Inventory

Cannabis inventory of \$15,429,658 as at June 30, 2023 increased as compared to March 31, 2023 as a result of (i) improvements to plant yields and improvements in post harvest processes implemented at the Chatham Facility during the reporting period; and (ii) the introduction and mix shift towards new higher value products such as vapes and infused pre-rolls.

Total Assets

The Company's assets of \$64,980,691 are primarily comprised of property, plant and equipment of \$40,392,918, (mainly land, buildings and productions rooms), inventory and biological assets of \$15,429,658 (work in progress and finished goods), and trade and other receivables of \$3,775,259.

Compared to March 31, 2023, total assets as at June 30, 2023 increased by \$15,004,344 upon the the acquisition of GreenSeal during the reporting period and were reduced by \$7,406,347 upon the liquidation of the Atlas Subsidiaries also during the reporting period.

Reconciliation of Non-GAAP Financial Measures to GAAP Measures

Net Revenue and Net Revenue from cannabis operations

The closest IFRS measure to net revenue and net revenue from cannabis operations is revenue as reported on the consolidated statement of loss and comprehensive loss, a reconciliation to which is found in the below table.

		For the 3 month period ended June 30, 2023	For the 15 month period ended March 31, 2023	Growth over prior year
Revenue	\$	7,329,712	6,212,241	18%
Less: excise taxes		(808,427)	(410,906)	
Net revenue		6,521,286	5,801,335	12%
Less: Revenue from non-cannabis goods – pharmacy operations		611,586	691,559	
Net revenue from cannabis products		5,909,700	5,109,776	16%

EBITDA and Adjusted EBITDA

The closest IFRS measure to EBITDA and Adjusted EBITDA is net loss as reported on the consolidated statement of loss and comprehensive loss, a reconciliation to which is found in the below table.

	For the 3 month period ended June 30, 2023	For the 15 month period ended March 31, 2023
Net Income / (loss)	5,678,991	(16,366,895)
Remove:		
Depreciation and Amortization	(1,265,520)	(1,144,480)
Share Based Compensation	(68,426)	(122,446)
Other income	81,543	138,749
Finance expense	(1,272,952)	(631,251)
Finance income	14,309	16,297
Impairment of intangible assets and goodwill	-	(7,373,056)
Loss on foreign exchange	3,349	(4,950)
EBITDA / (loss)	8,186,688	(7,245,758)
Non-recurring items included in EBITDA:		
Listing expense	-	(1,117,225)
Company acquisition expenses	(285,267)	(2,303,727)
Abnormal Destruction	(3,514,649)	-
Gain on loss of control	9,535,844	-
Gain on bargain purchase	2,090,146	-
Adjusted EBITDA / (loss)	360,614	(3,824,806)

Working Capital and Cannabis Inventory and bio-assets

These non-GAAP measures are a result of the addition or netting of IFRS financial measures, a reconciliation to which is found in the below table.

	As at June 30, 2023	As at June 30, 2022	As at March 31, 2023
Biological Assets	\$ 2,304,570	-	1,892,745
Inventories	13,125,088	-	11,000,939
Cannabis inventory and bio-assets	15,429,658	-	12,893,684
Add:			
Cash	1,372,542	17,550	2,614,498
Short-term Investments	33,312	-	35,833
Trade and other receivables	3,776,287	17,823	5,424,743
Deposits and prepaid assets	1,511,774	266,113	2,126,110
Deduct:			
Trade and other payables	19,379,945	218,482	22,375,179
Current portion of term debt	21,291,775	-	25,862,873
Current portion of lease liabilities	319,500	-	161,778
Income taxes payable	34,377	-	49,618
Deferred revenue	150,188	-	66,331
Contingent liability	1,073,620	-	-
Contingent consideration	177,868	-	-
Other current liabilities	10,118	-	11,902
Working capital surplus (deficiency)	(20,314,417)	83,004	(25,432,813)

Cash flows

Cash utilized by operating activities for the three months ended June 30, 2023, was \$945,613 compared to \$96,594 cash used in operating activities for the six months ended June 30, 2022.

During the three months ended June 30, 2023, the Company received \$52,840 from investing activities (nil\$ for six months ended June 30, 2022), representing cash acquired upon completion of the Transaction. Refer to Note 5 in the Interim Financial Statements.

During the three months ended June 30, 2023 and six months ended June 30, 2022, the Company did not raise funds from the issuance of shares and the exercise of stock options.

SUMMARY OF QUARTERLY RESULTS

This MD&A relates to the financial results of Cambrosia, as the reverse takeover acquirer. Having not previously been a reporting issuer, Cambrosia has not prepared financial statements on a quarterly basis and as a result, quarterly financial results are not available for any period prior to the three months ended December 31, 2022.

	For the 3 month period ended June 30, 2023	For 3 months ended March 31, 2023	For the 3 months ended December 31, 2022
Financial Results			
Revenue	\$ 7,329,712	\$ 6,212,241	-
Net Income (loss)	5,678,991	(16,366,895)	(1,579,407)
Earnings (loss) per share	0.04	(0.50)	(0.38)
	As at June 30, 2023	As at March 31, 2023	As at December 31, 2022
Statement of financial position			
Total Assets	\$ 64,980,691	\$ 61,653,037	73,273,009
Total liabilities	46,775,552	52,520,678	50,771,882

The financial results for the three month period ended December 31, 2023, are those of Cambrosia as the reverse take over acquirer and are not comparable to the results in subsequent quarters, which consolidate those of the other entities acquired as of December 30, 2022 upon completion of the Transaction.

The financial results for the three month period ended March 31, 2023, represent the first consolidated results of all of the entities acquired as of December 30, 2022 upon completion of the Transaction

The net income for the three months ending June 30, 2023 was impacted, to a very large extent, by the recognition of a gain on loss of control of the Atlas Subsidiaries of \$9,535,844 as well as the gain on bargain purchase of \$2,090,146 resulting from the acquisition of GreenSeal. These gains were partially offset by the loss from the abnormal destruction of inventory and biological assets resulting from the liquidation of the Gunn Facility, as well as related non-recurring expenses such as legal and professional fees of \$757,747. The Company's assets are primarily comprised of property, plant and equipment (mainly land, buildings and productions rooms) of \$40,392,918 (March 31, 2023 of \$36,412,516), inventory and biological assets of \$15,429,658 (March 31, 2023 of \$12,893,685), and trade and other receivables of \$3,776,287 (March 31, 2023 of 5,424,743).

Compared to March 31, 2023, total assets as at June 30, 2023 increased by \$15,004,344 s upon the acquisition of GreenSeal during the reporting period and were reduced by \$7,406,347 upon the liquidation of the Atlas Subsidiaries also during the reporting period. The Company's liabilities are primarily comprised of trade and other payables of \$19,380,045 (March 31, 2023 of \$22,375,175), and current portion of long-term debt of \$21,291,775 (March 31, 2023 of \$25,862,873).

LIQUIDITY AND CAPITAL RESOURCES

The Company had a working capital deficiency of (\$20,314,417) as at June 30, 2023 as compared to a working capital surplus of \$83,004 as at June 30, 2022. As at June 30, 2023, the Company had cash in the amount of \$1,372,542 as compared to \$17,550 at June 30, 2022.

Based on the current funds held, the Company does not have sufficient working capital for the short-term to maintain capacity. The Company's primary short-term liquidity needs are to make the down payments necessary to source product from some third parties, to fund its net operating losses and capital expenditures to maintain existing facilities, and lease payments.

The Company's ability to fund its short-term operating requirements depends on (i) future operating performance and cash flows, which are subject to economic, financial, competitive, business and regulatory conditions, and other factors, some of which are beyond its control and (ii) the Company's ability to access third party financing, including by way of a refinancing of existing debt or a sale or lease back of certain assets previously described. In addition, recent developments in the Canadian cannabis industry regarding potential garnishment of excise taxes in arrears (of which the Company has \$6,819,519), inserts material uncertainty into the Company's cash flow forecasts and increase the risk that it may not be able to fund its short-term operating requirements, absent third party financing.

The Company's medium-term liquidity needs primarily relate to debt repayments and lease payments and financing the Chatham Expansion to increase cash flow from operations and international market

penetration. These additional grow rooms at the Chatham Facility have been structurally completed but require additional infrastructure investments of up to approximately \$5 million, prior to onboarding them into active production.

Our long-term liquidity needs primarily relate to potential strategic plans. The Company does not have any current commitments for capital expenditures.

The Company's capital resources will continue to be insufficient, and to the extent available, costly, until it can sustain net positive cash flow from operations, whereupon the Company believes access to capital will increase and its cost will decrease.

The Company currently has \$15.1 million of principal owing on mortgages registered against the Chatham Facility. This secured indebtedness includes financial covenants including a requirement that the Company keep its debt-to-equity ratio at 1:1, and as of June 30, 2023, the Company was in violation of this covenant, which resulted in the long-term debt being classified as current. The lenders are contractually entitled to request for immediate repayment of the outstanding loan amount unless waived. The Company is in discussion with the lenders to secure a waiver of the default and while prior requests have been successful, there can be no assurance the Company will be successful again. See "*Risks and Uncertainties - The Company is in default of a covenant in a Mortgage registered against the Chatham Facility*".

In addition, the Company is in discussions with lenders for the refinancing of this debt prior to maturity in November 2024. The Company has appraised the Chatham Facility, including land and building, at a fair value upwards of \$30 million and is seeking to leverage the equity in the facility to secure additional financing for the short-term operations of the Company and the Chatham Expansion.

PROPOSED TRANSACTIONS

There are no undisclosed proposed transactions that will materially affect the Company.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has not entered into any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the financial performance or financial condition of the Company.

RELATED PARTY TRANSACTIONS

Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers.

The remuneration of directors and key management personnel during the reporting periods-ended June 30, 2023, is set out below:

<i>Related Party Reconciliation</i>	For the Reporting Period Ended June 30, 2023 (\$)
<i>Salaries and benefits</i>	400,391
<i>Share-based compensation</i>	27,523
<i>Professional fees</i>	171,475
<i>Total Related Party Compensation</i>	599,389

CHANGES IN ACCOUNTING POLICIES INCLUDING INITIAL ADOPTION

Accounting Pronouncements Adopted in Most Recently Completed Financial Year

The Company has applied the following amendments to IFRS Standards and Interpretations issued by the IASB that were effective for annual periods that begin on or after January 1, 2023. Their adoption has not had any material impact on the disclosures or on the amounts reported in these condensed interim financial statements.

Disclosure of Accounting Policies (Amendments to IAS 1)

The IASB has issued amendments to IAS 1 Presentation of Financial Statements which require entities to disclose their “material” accounting policy information rather than their “significant” accounting policies. The amendments explain that accounting policy information is material if omitting, misstating or obscuring that information could reasonably be expected to influence decisions that the primary users of the financial statements make on the basis of those financial statements. The amendments also clarify that accounting policy information may be material because of its nature, even if the related amounts are immaterial.

Definition of Accounting Estimates (Amendments to IAS 8)

The IASB has issued amendments to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors which introduce a definition of accounting estimates and provide other clarifications to help entities distinguish accounting policies from accounting estimates. Under the amendments, accounting estimates are defined as “monetary amounts in financial statements that are subject to measurement uncertainty”. The amendments also emphasize that a change in an accounting estimate that results from new information or new developments is not an error correction, and that changes in an input or a measurement technique used to develop an accounting estimate are considered changes in accounting estimates if those changes in an input or measurement technique are not the result of an error correction.

Deferred Tax related to Assets and Liabilities arising from a Single Transaction (Amendments to IFRS 1 and IAS 12)

The IASB has issued amendments to IFRS 1 First-time Adoption of International Financial Reporting Standards and IAS 12 Income Taxes which clarify that the initial recognition exemption set out in IAS 12 does not apply to transactions that give rise to equal taxable and deductible temporary differences. The aim of the amendments is to reduce diversity in the reporting of deferred tax on leases and decommissioning obligations.

New Accounting Pronouncements

Other than as set forth below the Company has does not expect to adopt any in the period subsequent to the reporting period.

Amendments to IAS 1: Classification of Liabilities as Current or Non-current

The IASB has published Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) which clarifies the guidance on whether a liability should be classified as either current or non-current. The amendments: • clarify that the classification of liabilities as current or non-current should only be based on rights that are in place “at the end of the reporting period” • clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability • make clear that settlement includes transfers to the counterparty of cash, equity instruments, other assets or services that result in extinguishment of the liability. This amendment is effective for annual periods beginning on or after January 1, 2024. Earlier application is permitted. The extent of the impact of adoption of this amendment has not yet been determined.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

The Company's financial instruments consist of cash, cash equivalents, accounts payable, accounts receivable, the AgMedica Class B Preferred Shares, and other financial assets, term debt and accrued liabilities. Financial instruments are measured either at fair value or at amortized cost. The table below lists the valuation methods used to determine the fair value of each financial instrument.

Financial asset / liability	IFRS 9
Cash	Amortized cost
Accounts receivable	Amortized cost
Other financial assets	Amortized cost
Accounts payable and accrued liabilities	Amortized cost
Term debt	Amortized cost
Deposits	Amortized cost
Class B - preferred shares	Amortized cost
Contingent consideration	Amortized cost
Contingent liability	Amortized cost

The Company classifies its cash and cash equivalents at amortized cost. The carrying values of accounts payable, amounts payable and consideration payable, which have been classified as financial liabilities, are measured at amortized cost using the effective interest method.

The carrying values of the financial instruments at June 30, 2023 are summarized in the following table:

Financial asset / liability	Carrying Value
Cash	1,372,542
Trade and other receivables	3,775,787
Other financial assets	33,312
Trade and other payables	19,380,045
Term debt	21,311,209
Deposits and prepaid assets	1,511,774
Class B - preferred shares	854,328
Contingent consideration	177,868
Contingent liability	1,073,620

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether the price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company considers the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value measurements are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs). The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. Further information on fair value measurements is available in Note 2 of the Financial Statements.

The carrying values of cash, accounts receivable, and accounts payable and accrued liabilities approximate their fair values due to their short-term to maturity. The fair value of the promissory notes and term debt and equipment financings also approximate their fair value.

The risks associated with the Company's financial instruments and how these risks are managed are summarized below.

Credit risk

Credit risk is the risk of potential loss if a counter party to a financial instrument fails to meet its payment obligations. The Company is exposed to credit risk with respect to its accounts receivable in the aggregate amount of \$3,775,787 as at June 30, 2023 (June 30, 2022 - \$17,823). Cash is held with certain Canadian and Israeli financial institutions with high credit worthiness.

The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. The Company has assessed that it has limited customer credit risk due to the fact that accounts receivable is primarily from the sale of cannabis to Canadian government agencies and large retail outlets and have payment terms of 30–60 days. For smaller customers, payment is fulfilled through the processing of a credit card or obtaining payment in advance of delivery, therefore limiting the Company's credit risk exposure on these types of transactions. Pharmacy operations in Israel do not extend credit to its retail customers.

To mitigate credit risk exposure for its international customers, the Company generally receives a minimum of a 50% deposit prior to shipment.

The aging of the Company's trade receivables has changed significantly between June 30, 2023 and June 30, 2022 due to the increase in operations and the Transaction. As at June 30, 2023, no financial assets were past due except for the outstanding accounts receivable, of which \$36,320 (June 30, 2022 - \$nil) was greater than 60 days outstanding as at June 30, 2023.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its obligations as they become due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements, and when possible, raises capital as required to support investment in production facilities and working capital requirements.

Based on the current funds held, the Company does not have sufficient working capital for the short term, and thus will need to rely upon financing from shareholders and/or debt holders, or from new investors, or from the refinancing or sale and leaseback of its Chatham, Ontario facility, to obtain sufficient working capital. There is no assurance that such financing will be available on terms and conditions acceptable to the Company or at all.

Credit Risk

The Company, through its international customers and vendors, is exposed to currency risk. As at June 30, 2023, \$7,082,993 (June 30, 2022 - \$301,486) of its financial assets were denominated in NIS. At June 30, 2023, \$3,985,325 (June 30, 2022 - \$218,482) of its financial liabilities, were denominated in NIS.

The Company is exposed to the NIS and a 10% strengthening or weakening in the NIS against the Canadian dollar on financial assets and financial liabilities would result in a decrease or increase of approximately \$309,767 (June 30, 2022 - \$21,848) in net loss for the reporting period-ended June 30, 2023.

The Company has not entered into any hedging agreements or purchased any financial instruments to hedge its foreign currency risk.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to cash flow interest rate risk.

As at June 30, 2023, the Company does not hold any financial liabilities with variable interest rates, other than short-term revolving credit facilities at its pharmacy subsidiaries in Israel. Atlas does maintain bank accounts and occasionally government investment certificates which earn interest at variable rates, but it does not believe it is currently subject to any significant interest rate risk.

Interest rate risks on the interest-bearing financial liabilities are mostly limited due to the fact that the Company's substantial financial liabilities are fixed rate interest instruments carried at amortized cost. In Israel, the Company's pharmacy subsidiaries have bank lines of credit, with fluctuating interest rates, but their impact on the Company's overall interest rate risk is limited.

Foreign Currency Risk

The Company, through its international customers and vendors is exposed to currency risk. As at June 30, 2023, \$7,082,993 of the Company's financial assets (June 30, 2022 - \$301,486) and \$3,985,325 of the Company's financial liabilities (June 30, 2022 - \$218,482) are translated to and denominated in Canadian dollars.

The Company manages its exposure to foreign currency fluctuations by maintaining foreign currency bank accounts to offset foreign currency payables and planned expenditures.

OUTSTANDING SHARE DATA

The Company has authorized an unlimited number of common shares without par value.

As of the date of this MD&A, the Company has 158,679,139 shares issued and outstanding, 11,681,326 stock options and 300,000 restricted share units.

Lastly, (i) in connection with the acquisition of GreenSeal and the recent receipt of a clearance certificate from the CRA, the Company is obligated to issue the 2,387,642 Withheld Shares; and (ii) subject to full or partial revocation of the existing cease trade order, the Company will issue 3,693,444 Loan Consideration Shares (as defined below).

RISKS AND UNCERTAINTIES

The Company is subject to a number of risks and uncertainties. The following discussion summarizes certain risk factors that apply to the Company's business and may affect the Company's financial condition, results of operation or business and that could cause actual results to differ materially from those expressed in our forward-looking statements. These risks and uncertainties are not the only ones facing the Company. Refer to the Company's MD&A for the financial year ended March 30, 2023, dated April 9, 2024 for a complete list of risk factors impacting the Company. Also, additional risks and uncertainties not currently known to the Company, or that the Company currently considers immaterial, may also materially adversely affect the business, financial condition and results of operations, or the trading price of the Company's Shares if any such risks actually occur.

The Company's ability to continue as a going concern depends on several factors, primarily securing additional funding.

During the three months ended June 30, 2023, the Company had a net income of \$5,678,991 and as at June 30, 2023 had cumulative deficit of \$10,828,990 and current liabilities exceeding current assets by \$20,314,417. The above events and conditions indicate there is material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent, among, other things, upon its capability to grow its revenue or reduce its cost base, to achieve self-sustaining operations and, in the meantime, to obtain the necessary financing to meet its obligations and repay its liabilities when they become due. External financing, predominantly by the issuance of equity and debt, is sought to finance the operations of the Company; however, there can be no certainty that such funds will be available at terms acceptable to the Company, or at all.

The Company is in default of a covenant in a Mortgage registered against the Chatham Facility

Any default under our existing debt that is not waived by the applicable lenders could materially and adversely impact our results of operations and financial results, may impact the Company's ability to continue as a going concern, and may have a material adverse effect on the trading price of our Shares (once and if the FFCTO is lifted).

We are required to comply with the covenants in our debt instruments. These covenants may create a risk of default on our debt if we cannot satisfy or continue to satisfy these covenants. If the Company cannot comply with a debt covenant or anticipate that it will be unable to comply with a debt covenant under any debt instrument it is party to, management may seek a waiver and/or amendment to the applicable debt instrument in respect of any such covenant in order to avoid any breach or default that might otherwise result therefrom. If we default under a debt instrument and the default is not waived by the lender(s), the debt extended pursuant to all of its debt instruments could become due and payable prior to there stated due date. If such event were to occur, the Company cannot give any assurance that (i) its lenders will agree to any covenant amendments or waive any covenant breaches or defaults that may occur, and (ii) it could pay this debt if it became due prior to its stated due date. Accordingly, any default by us on existing debt that is not waived by the applicable lenders could materially adversely impact our results of operations and financial results, may impact the Company's ability to continue as a going concern, and may have a material adverse effect on the trading price of our Shares.

In that regard, Atlas is subject to externally imposed capital covenants related to secured indebtedness registered against the Chatham Facility and must keep its debt-to-equity ratio at 1:1, and as of June 30, 2023, was in violation of this covenant, which resulted in the long-term debt being classified as current.

The Company is in discussion with the applicable lender regarding a waiver of this breach and possibly repayment, in the event discussions regarding a refinancing of the Chatham Facility are successful.

Garnishment of Excise Tax Arrears Would Materially and Adversely Affect The Company's Near Term Cash Flow

As stated above, in an industry wide effort to collect substantial arrears, CRA has requested that provincially owned cannabis wholesalers to garnish payments intended for licensed producers, such as the Company. The Company has an arrears balance with the CRA of \$6,819,519 and potential garnishment, without third party financing and/or some negotiation of the timing of payment of the arrears will materially adversely affect the Company's future financial performance. The Company is in discussion with the CRA regarding payment of the arrears on a schedule that will mitigate the effect on the Company's near term cash position.

Refinancing debt on the Chatham Facility as an opportunity to increase working capital for AGB

The Company currently has \$15.1 million in principal mortgages secured against the Chatham Facility which matures in November 2024. The Company is in discussions with lenders for the refinancing of this debt, however upon maturity of the debt, there can be no certainty that refinancing will be available at terms acceptable to the Company.

Our continued growth requires additional financing, which may not be available on acceptable terms or at all.

Our continued development and our ability to meet planned growth and increased cash flow for operations, particularly the Chatham Expansion, requires additional financing. The Company has appraised the Chatham facility, including land and building, at a fair value upwards of \$30M and is seeking to further leverage the equity in the facility to secure additional financing for the Chatham Expansion and other operations of the Company.

The failure to raise such capital would result in the delay or indefinite postponement of our current business strategy or our ceasing to carry on business. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be available on favorable terms. If additional funds are raised through issuances of equity, equity-linked securities, or convertible debt securities, existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences, and privileges superior to those of holders of Shares. In addition, from time to time, we may enter into transactions to acquire assets or equity securities of other companies. These transactions may be financed wholly or partially with debt, which may increase our debt levels above industry standards and our ability to service such debt. Any debt financing obtained in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which could make it more difficult for us to obtain additional capital and pursue business opportunities, including potential acquisitions. Debt financings may contain provisions, which, if

breached, entitle lenders to accelerate repayment of debt and there is no assurance that we would be able to repay such debt in such an event or prevent the enforcement of security, if any, granted pursuant to such debt financing.

An economic downturn of global capital markets may make raising additional capital more difficult. If uncertain market conditions persist, the Company's ability to raise capital could be jeopardized, which could have an adverse impact on the Company's operations and the trading price of the Company's shares.

KEY DEVELOPMENTS SUBSEQUENT TO THE THREE MONTHS ENDED JUNE 30, 2023

Purchase Order and Accounts Receivable Sales

On July 6, 2023 the Company entered into an arrangement to sell certain accounts receivables in exchange for an advance of 75% of the accounts receivables sold with the remaining 25% to be remitted net of fees and charges upon collection. On September 9, 2023, the Company amended the arrangement to include the sale of certain purchase orders which, once the purchase order is fulfilled, convert into a sold receivable and the Company receives an advance of 65% of the receivable. The receivables are sold on a non-recourse basis, and the Company pays a fee of 1.8% per month of the uncollected amounts advanced up to \$1,000,000, and 1.67% per month on amounts advanced that are greater than \$1,000,000. In addition, the Company is obligated to pay an unused facility fee of 2% per annum on the unused amount of the facility.

Failure to File Cease Trade Order

On August 8, 2023, the Ontario Securities Commission (the "**OSC**"), as the principal regulator, issued a failure to file cease trade order (the "**FFCTO**"), upon the Company's failure to file the financial statements and related MD&A and certifications (the "**Annual Filings**") by July 31, 2023. On April 9, 2024 the Company completed its Annual Filings.

As a consequence of the delay in completing the Annual Filings, the Company is also delayed in filing its interim financial report and related management's discussion and analysis and certifications for the interim period ended June 30, 2023, September 30, 2023 and December 31, 2023 that were due August 29, 2023, November 29, 2023, and February 29, 2024 respectively/

The FFCTO prohibits the trading by any person of any securities of the Company in each jurisdiction in Canada in which the Company is a reporting issuer and in which Multilateral Instrument 11-103 – *Failure-to-File Cease Trade Orders in Multiple Jurisdictions* applies, including trades in the Shares made through the CSE, for as long as the FFCTO is in effect, with limited exceptions.

On March 20, 2024, the Company made application to the OSC for a partial revocation order permitting the issue of the Loan Consideration Shares.

New Loan

On February 6, 2024 Shahar Management Group Company (K.S.N.) Ltd. ("**Shahar**"), an entity controlled by Avi Elkayam, an insider of the Company, has made a loan to Cambrosia, a wholly-owned subsidiary of the Company in the principal amount of 3,000,000 NIS (approximately \$1,110,000 CAD) (the "**Loan**").

The Loan was made pursuant to an agreement dated January 8, 2024, as amended on February 1, 2024, and further amended on March 12, 2024, between Cambrosia and Shahar (the "**Loan Agreement**"). The Loan has a term of two years commencing on February 1, 2024, and bears interest at a rate of 9.75% per annum. Loan repayment obligations for the first 12 months of the term are on an interest-only basis, and thereafter monthly payments of interest and principal.

Pursuant to the Loan Agreement, Cambrosia deposited 250,000 NIS in a closed bank account to ensure timely interest payments for the first year of the term. Cambrosia has the option to request an extension of the term of the Loan by an additional 12 months, for an aggregate repayment term of three years.

Cambrosia's obligations under the Loan Agreement are secured by a pledge of its 51% interest in its three pharmacies located in Israel and its interest in any other subsequently acquired medical cannabis

pharmacies and guaranteed by the Company. Shahar has the right to enforce its' security interest in the pharmacies should the FFCTO not be lifted by May 15, 2024. In addition to the applicable interest on the Loan payable by Cambrosia, subject to and conditional upon the revocation of the FFCTO, Atlas will issue to Avi Elkayam, as sole shareholder of Shahar and/or to Shahar 3,693,444 Shares (the "**Loan Consideration Shares**").

ADDITIONAL INFORMATION

Additional information relating to the Company, including the Interim Financial Statements and the Company's Annual Information Form, can be found on SEDAR at sedarplus.ca.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This MD&A includes "forward-looking information" within the meaning of applicable securities legislation, that relate to our current expectations and views of future events. Statements or information which are not purely historical are forward-looking statements and include any statements or information regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as "anticipate", "objective", "may", "will", "should", "expect", "believe", "estimate", "potential", "plan", "project" or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements and information may include, among other things, statements or information relating to the business strategy (including expected growth rate) of Atlas, potential sources of capital, any estimate of potential earnings and margins, the completion of any transaction including additional acquisitions, financings and re-financings, expected market growth and market penetration, timing of product development (both for future products and enhancements of existing products), expectations regarding expenses, sales, operations, our estimates regarding our capital requirements and our ability to obtain additional financing, our expectations for the cost and timing of achieving our business objectives, our competitive position, and anticipated trends and challenges in the markets in which we operate including the regulatory environment.

Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Atlas will operate in the future, including: general business and economic conditions; the regulatory environment, the demand for our products; anticipated costs and ability to achieve goals, business plan and growth strategy; the availability of financing on reasonable terms as needed; our ability to attract and retain skilled staff; our ability to complete any contemplated transactions; and that there will be no regulation or law that will prevent us from operating our business or render it more costly to do so. Although Atlas believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Forward-looking statements and information are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or information, including but not limited to: the commencement of garnishment proceedings to collect excise tax in arrears, the possibility that the secured lender in respect of the Chatham Facility does not waive the breach of covenant and commences enforcement proceedings against the collateral, that short term financing is not secured, that the FFCTO is not revoked in part or in whole, our ability to access capital on reasonable terms in the medium term; demand for our products, business, economic and capital market conditions; the ability to expand our business internationally; the ability of the Company to make payments of principal and interest on its outstanding debt; the ability to refinance outstanding debt if required; the ability to manage our operating expenses which will increase significantly through business expansion and may adversely affect our financial condition; our ability to manage working capital; our ability to obtain additional financing, continued hostilities in the Middle East, potential dilution of the Company's share capital from future financing; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to remain competitive as competitors develop and release products; the ability to find and finance suitable acquisitions; legal and regulatory uncertainties; the uncertainty of the outcome of current ongoing litigation; risks inherent in foreign operations in the countries in which the Company or its subsidiaries operates, including political, economic, legal, military and sovereign risk; market volatility in response to heightened inflation and the impact on demand and pricing for our products; exchange rate fluctuation; price and volume volatility of the Company's shares; our relationships with our

customers, distributors, suppliers and business partners; volatility in cannabis supply and demand; logistics issues, delays or delivery costs; ability to meet target production; alteration of supply contracts; conflicts of interest; quality control; our ability to attract, retain and motivate qualified personnel; our dependence on key personnel and the sufficiency of their expertise in managing a public company; our failure to develop new products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; product liability and recall; the risk that consumer interest in and sentiment towards Atlas products adversely changes; the impact of COVID-19 or other viruses and diseases on Atlas' ability to operate; equipment failures; unanticipated increases in operating costs; security threats; government regulations and laws regulating cannabis production and distribution and changes thereto; the availability and validity of licenses and permits required to operate the Company's business; changes or developments affecting the Company's production facilities; and failure of counterparties to perform their contractual obligations.

Further, Atlas is a holding company and essentially all of its operating assets are the capital stock of its subsidiaries. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements or information.

The forward looking information included in this MD&A is expressly qualified in its entirety by this cautionary statement. The Company cautions that the foregoing lists of assumptions, risks and uncertainties is not exhaustive.